Oncoustics: AI Accuracy of Prostate Cancer Biopsies
JANUARY 07, 2020
In a collaborative study, over 1000 labeled data sets from Exact Imaging’s ExactVu™ micro-ultrasound system were used for validation of Oncoustics’ cancer recognition algorithm on clinical data from transrectal prostate cancer biopsies.
SAN FRANCISCO, CA and TORONTO, CANADA -- (December 9, 2019) Oncoustics (www.oncoustics.com), one of the world’s leaders in Artificial Intelligence (AI) based analytics for ultrasound enabling real-time diagnosis and non-invasive liver surveillance, announced it has completed the first phase of a collaborative study with Exact Imaging to support guidance for applications in the prostate. Operating on a large dataset obtained by the ExactVu 29 MHz micro-ultrasound system, the Oncoustics’ software demonstrated the feasibility for enhanced applications, where in this example, urologists might obtain real-time labels from Exact’s near-microscopic resolution of prostate biopsies. (The ExactVu system provides the highest real-time resolution for guidance of prostate biopsies.)

“There is increasing movement towards generalized application of ultrasound signal interpretation by validated computation,” says Michael Weil, Oncoustics’ CEO. “With this evaluation, beyond liver pathology, our technology can now be developed in the common clinical settings, such as targeted prostate biopsies and cognitive fusion biopsies.”

“The Oncoustics’ technology broadens our options and could be performed in the clinic or in an outpatient center.” says Anand Patel, MD, Chief of Interventional Radiology at Providence Little Company of Mary Torrance and San Pedro Hospitals. “As applications and strategies evolve, there is huge potential for enhanced, non-invasive tissue characterization, enhanced histopathology and the likelihood for optimization of clinical workflow along with advancing diagnostic accuracy of liver or prostate biopsies.”

Oncoustics’ ultrasound solution does not enhance image resolution. Rather, it mines seen and unseen signal information and yields significantly better categorization of tissue function and pathology than is possible with conventional or other AI-based approaches. It can markedly expand the functionality of even low-cost, point-of-care ultrasound systems.
About Exact Imaging
Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system’s 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)), and Canada (Health Canada medical device license).

For further information, please contact:

Randy AuCoin, President & CEO
Exact Imaging
About Oncoustics
Oncoustics (www.oncoustics.com) is a world leader in AI-based ultrasound data extraction enabling real-time imaging and non-invasive diagnosis in the medical market starting with liver disease. Oncoustics’ platform operates in a hardware agnostic fashion, and enables a whole new level of access to care with the benefits of ease of use, affordability, and optimizing current clinical workflow. Using the Oncoustics’ platform, physicians will be able to visualize areas of interest in the liver or prostate, and specifically retrieve analysis from those areas. The Oncoustics’ solution for ultrasound, including liver and prostate applications, will be submitted for regulatory approval in the United States (FDA 510(k)), Canada (Health Canada medical device license) and the European Union (CE Mark).

Beth Rogozinski, CEO